Nephros (NASDAQ:NEPH) Stock Rating Upgraded by Zacks Investment Research


Nephros (NASDAQ:NEPH – Get an Assessment) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note released Saturday, reports.

According to Zacks, “Nephros is developing technology and advanced therapeutics for end-stage renal disease, or ESRD, that would meet both the treatment needs of patients and the clinical and financial needs of the treatment provider.”

Separately, B. Riley cut his price target on Nephros from $11.25 to $8.00 and set a “buy” rating on the stock in a Wednesday, Feb. 16 research report.

Nephros stock opened at $4.15 on Friday. The stock’s 50-day moving average price is $4.64 and its 200-day moving average price is $6.54. The company has a market capitalization of $42.57 million, a PE ratio of -10.12 and a beta of 1.26. The company has a debt ratio of 0.01, a quick ratio of 3.70 and a current ratio of 5.70. Nephros has a 1-year low of $3.77 and a 1-year high of $11.67.

Nephros (NASDAQ:NEPH – Get Rating) last released its quarterly results on Wednesday, February 23. The company reported ($0.11) EPS for the quarter, missing the ($0.10) consensus estimate of ($0.01). The company posted revenue of $2.77 million for the quarter, versus analyst estimates of $2.81 million. Nephros had a negative return on equity of 25.91% and a negative net margin of 37.74%. During the same period last year, the company posted ($0.08) earnings per share. On average, analysts expect Nephros to post -0.38 earnings per share for the current fiscal year.

(A d)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Several institutional investors and hedge funds have recently changed their positions in the company. Vanguard Group Inc. increased its position in Nephros shares by 3.9% in the second quarter. Vanguard Group Inc. now owns 99,936 shares of the company valued at $1,014,000 after purchasing an additional 3,741 shares in the last quarter. Elkhorn Partners Limited Partnership increased its position in Nephros shares by 78.8% in the fourth quarter. Elkhorn Partners Limited Partnership now owns 15,200 shares of the company valued at $90,000 after buying an additional 6,700 shares last quarter. Morgan Stanley increased its equity stake in Nephros by 186.3% in the third quarter. Morgan Stanley now owns 13,837 shares of the company valued at $121,000 after acquiring 9,004 additional shares in the last quarter. Cowen Prime Advisors LLC increased its stake in Nephros shares by 5.4% in Q3. Cowen Prime Advisors LLC now owns 660,150 shares of the company valued at $5,790,000 after acquiring 33,700 additional shares in the last quarter. Finally, Wexford Capital LP purchased a new equity stake in Nephros in Q4 valued at approximately $646,532,000. 15.14% of the shares are currently held by institutional investors.

About Nephros (Get an assessment)

Nephros, Inc is a medical device company engaged in the development and sale of liquid purification filters and in-line medium dilution hemodiafiltration system. The Company operates in two segments: water filtration and kidney products. The water filtration segment includes both the medical device and commercial filtration product lines.

Read more

Get a Free Copy of Zacks Research Report on Nephros (NEPH)

For more information on Zacks Investment Research’s research offerings, visit

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Nephros right now?

Before you consider Nephros, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Nephros wasn’t on the list.

Although Nephros currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here


Comments are closed.